Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 14 April, 2024|Author: Getaka | Social: X Twitter Profile
Stock Ticker - BSE: 532989 | NSE: BAFNAPH

Fundamental Analysis of Bafna Pharmaceuticals Ltd

About the Company - Bafna Pharmaceuticals Ltd

No data availabale for About the Company
INDUSTRYADDRESSCONTACT
Industry not foundAddress not foundContact not found
Management Data not Available

Basic Stock Data of Bafna Pharmaceuticals Ltd

Last Updated: April 9, 2024, 3:25 am

Market Cap 209 Cr.
Current Price 88.5
High / Low126/75.9
Stock P/E18.6
Book Value 34.8
Dividend Yield0.00 %
ROCE15.9 %
ROE16.4 %
Face Value 10.0

Data Source: screener.in

Competitors of Bafna Pharmaceuticals Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Bacil Pharma Ltd 10.3 Cr. 17.417.4/4.68 2.120.00 %12.6 %12.9 % 10.0
Biofil Chemicals & Pharmaceuticals Ltd 109 Cr. 67.079.0/41.0165 10.90.00 %4.73 %3.28 % 10.0
Shilpa Medicare Ltd 4,390 Cr. 506534/228 2050.00 %0.81 %1.71 % 1.00
Suven Life Sciences Ltd 2,523 Cr. 116129/55.0 15.50.00 %52.7 %53.5 % 1.00
SMS Pharmaceuticals Ltd 1,730 Cr. 204218/65.041.6 60.70.15 %3.66 %0.84 % 1.00
Industry Average1,752.46 Cr182.0841.3258.840.03%14.90%14.45%4.60

Bafna Pharmaceuticals Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales17.4821.8421.2628.4420.4614.9816.9321.9634.2242.2441.9540.6828.44
Expenses15.2717.6417.7722.7417.6315.3615.2719.4231.1834.6235.6636.6730.51
Operating Profit2.214.203.495.702.83-0.381.662.543.047.626.294.01-2.07
OPM %12.64%19.23%16.42%20.04%13.83%-2.54%9.81%11.57%8.88%18.04%14.99%9.86%-7.28%
Other Income0.040.310.17-1.790.491.041.300.641.930.261.870.160.98
Interest0.330.380.110.110.410.210.310.450.580.700.600.440.58
Depreciation1.021.501.461.421.211.401.291.121.401.531.211.241.27
Profit before tax0.902.632.092.381.70-0.951.361.612.995.656.352.49-2.94
Tax %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%4.96%0.00%0.00%0.00%
Net Profit0.902.642.092.381.70-0.951.361.613.005.376.352.48-2.94
EPS in Rs0.381.120.881.010.72-0.400.570.681.272.272.681.05-1.24

Last Updated: April 6, 2024, 9:30 am

Bafna Pharmaceuticals Ltd Quarterly Chart

Bafna Pharmaceuticals Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales12416717710085654644427185115159
Expenses10514615611682708157416173100138
Operating Profit182121-163-5-35-13110121621
OPM %15%13%12%-16%3%-8%-77%-30%3%14%14%14%13%
Other Income1314011310-231-034
Interest811121212117201122
Depreciation6885444334555
Profit before tax5526-13-19-14-18-25651217
Tax %61%25%40%-0%3%4%-15%-8%0%0%0%2%
Net Profit2416-12-18-16-20-25651117
EPS in Rs1.132.080.723.28-6.53-9.90-6.95-8.34-106.532.462.214.797.27
Dividend Payout %0%29%0%0%0%0%0%0%0%0%0%0%

Bafna Pharmaceuticals Ltd Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)100.00%-75.00%500.00%-300.00%-50.00%11.11%-25.00%-25.00%124.00%-16.67%120.00%
Change in YoY Net Profit Growth (%)0.00%-175.00%575.00%-800.00%250.00%61.11%-36.11%0.00%149.00%-140.67%136.67%

Bafna Pharmaceuticals Ltd Growth

Compounded Sales Growth
10 Years:-4%
5 Years:20%
3 Years:40%
TTM:74%
Compounded Profit Growth
10 Years:18%
5 Years:18%
3 Years:100%
TTM:116%
Stock Price CAGR
10 Years:13%
5 Years:56%
3 Years:-13%
1 Year:0%
Return on Equity
10 Years:-19%
5 Years:1%
3 Years:13%
Last Year:16%

Bafna Pharmaceuticals Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital1819191919192424224242424
Reserves40495053412217-34933385059
Borrowings8191996480824746315112317
Other Liabilities69845450454440541714173336
Total Liabilities207243223185185167128121718690130135
Fixed Assets70666349474340373536394041
CWIP0000000001022
Investments1111818181100000
Other Assets13617515811812010686823650518892
Total Assets207243223185185167128121718690130135

Bafna Pharmaceuticals Ltd Reserves and Borrowings Chart

Bafna Pharmaceuticals Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 283519-314-7-1-34-14105
Cash from Investing Activity -37-6-556-1-838433-5-7-7
Cash from Financing Activity -1-11-14-664-5-31-2712-510
Net Cash Flow-918-18-00-0006-7-28

Bafna Pharmaceuticals Ltd Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days241187192303291302195208524963130
Inventory Days9263786692118102122208154185129
Days Payable216215116149169164265517229107113165
Cash Conversion Cycle1173515522021425531-188319613594
Working Capital Days21315020425032020779-1689172148150
ROCE %11%9%9%-13%-0%-6%-36%-21%-3%10%11%16%

Bafna Pharmaceuticals Ltd Financial Efficiency Indicators Chart

Bafna Pharmaceuticals Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters91.74%90.39%90.40%90.42%90.42%90.12%90.00%90.01%89.99%89.99%88.73%88.42%
Public8.26%9.61%9.60%9.58%9.58%9.88%10.00%9.98%10.00%10.00%11.27%11.57%
No. of Shareholders8,6038,3308,0687,9107,3267,2237,2757,1997,1206,9927,3547,367

Bafna Pharmaceuticals Ltd Shareholding Pattern Chart

No. of Bafna Pharmaceuticals Ltd Shareholders

This stock is not held by any mutual fund

Bafna Pharmaceuticals Ltd ROCE Trend

Bafna Pharmaceuticals Ltd EPS Trend

Bafna Pharmaceuticals Ltd Key Financial Ratios

MonthMar 20Mar 19Mar 18Mar 17Mar 16
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)-15.52-11.48-7.15-10.43-8.80
Diluted EPS (Rs.)-15.52-11.48-7.15-10.43-8.80
Cash EPS (Rs.)-89.52-6.29-5.47-8.17-5.51
Book Value[Excl.RevalReserv]/Share (Rs.)-17.597.9715.7322.5730.95
Book Value[Incl.RevalReserv]/Share (Rs.)-17.597.9715.7322.5730.95
Revenue From Operations / Share (Rs.)179.5418.3319.9434.8245.73
PBDIT / Share (Rs.)6.25-5.36-1.61-2.501.34
PBIT / Share (Rs.)-7.56-6.83-3.29-4.76-1.27
PBT / Share (Rs.)-103.32-7.30-6.22-10.91-8.21
Net Profit / Share (Rs.)-103.32-7.76-7.15-10.43-8.12
NP After MI And SOA / Share (Rs.)-104.54-7.98-7.07-10.23-7.52
PBDIT Margin (%)3.48-29.26-8.05-7.182.92
PBIT Margin (%)-4.20-37.28-16.47-13.68-2.76
PBT Margin (%)-57.54-39.86-31.19-31.34-17.95
Net Profit Margin (%)-57.54-42.32-35.84-29.95-17.74
NP After MI And SOA Margin (%)-58.22-43.52-35.48-29.38-16.44
Return on Networth / Equity (%)0.00-99.01-44.12-44.73-24.28
Return on Capital Employeed (%)-3.29-33.22-9.90-9.17-2.41
Return On Assets (%)-34.67-15.79-12.09-10.70-7.27
Long Term Debt / Equity (X)-0.711.210.610.910.60
Total Debt / Equity (X)-0.712.431.231.931.39
Asset Turnover Ratio (%)0.440.330.300.360.44
Current Ratio (X)2.110.680.810.941.29
Quick Ratio (X)1.440.550.630.741.11
Inventory Turnover Ratio (X)2.242.661.550.890.97
Interest Coverage Ratio (X)15.48-5.97-0.54-0.400.19
Interest Coverage Ratio (Post Tax) (X)-18.72-8.10-1.44-0.69-0.16
Enterprise Value (Cr.)-3.2969.21109.10134.30133.55
EV / Net Operating Revenue (X)-0.071.602.312.071.57
EV / EBITDA (X)-2.22-5.45-28.71-28.7653.52
MarketCap / Net Operating Revenue (X)0.040.591.400.840.65
Price / BV (X)-0.491.361.751.290.96
Price / Net Operating Revenue (X)0.040.591.400.840.65
EarningsYield-11.80-0.72-0.25-0.34-0.25

Bafna Pharmaceuticals Ltd Profitability Ratios (%)

Bafna Pharmaceuticals Ltd Liquidity Ratios

Bafna Pharmaceuticals Ltd Liquidity Ratios (%)

Bafna Pharmaceuticals Ltd Interest Coverage Ratios (X)

Bafna Pharmaceuticals Ltd Valuation Ratios

Fair Value / Intrinsic Value of Bafna Pharmaceuticals Ltd

Fair Value: 108.28

The stock is undervalued by 22.35% compared to the current price ₹88.5

Calculation basis:

  • Fair value = (P/E Ratio * (Return on Equity / 100) * Book Value) * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

*Investments are subject to market risks

Strength and Weakness of Bafna Pharmaceuticals Ltd

StrengthWeakness
    1. The stock has a low average ROCE of -1.08%, which may not be favorable.
    2. The stock has a high average Working Capital Days of 163.83, which may not be favorable.
    3. The stock has a high average Cash Conversion Cycle of 99.58, which may not be favorable.
    4. The company has higher borrowings (50.69) compared to reserves (38.31), which may suggest financial risk.
    5. The company has not shown consistent growth in sales (98.00) and profit (-2.77).

    Should I Buy Bafna Pharmaceuticals Ltd Share Now?

    • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bafna Pharmaceuticals Ltd:
      1. Net Profit Margin: -57.54%
        • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
      2. ROCE: -3.29% (Industry Average ROCE: 26.14%)
        • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
      3. ROE%: 0.00% (Industry Average ROE: 23.86%)
        • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
      4. Interest Coverage Ratio (Post Tax): -18.72
        • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
      5. Quick Ratio: 1.44
        • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
      6. ✓ Stock P/E: 18.6 (Industry average Stock P/E: 45.74)
        • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
      7. ✓ Total Debt / Equity: -0.71
        • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
      The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
      Stock Rating: ★★☆☆☆

    FAQ

    What is the latest fair value of Bafna Pharmaceuticals Ltd?

    The latest fair value of Bafna Pharmaceuticals Ltd is ₹108.28.

    What is the Market Cap of Bafna Pharmaceuticals Ltd?

    The Market Cap of Bafna Pharmaceuticals Ltd is 209 Cr..

    What is the current Stock Price of Bafna Pharmaceuticals Ltd as on 09 April 2024?

    The current stock price of Bafna Pharmaceuticals Ltd as on 09 April 2024 is 88.5.

    What is the High / Low of Bafna Pharmaceuticals Ltd stocks in FY 2024?

    In FY 2024, the High / Low of Bafna Pharmaceuticals Ltd stocks is ₹126/75.9.

    What is the Stock P/E of Bafna Pharmaceuticals Ltd?

    The Stock P/E of Bafna Pharmaceuticals Ltd is 18.6.

    What is the Book Value of Bafna Pharmaceuticals Ltd?

    The Book Value of Bafna Pharmaceuticals Ltd is 34.8.

    What is the Dividend Yield of Bafna Pharmaceuticals Ltd?

    The Dividend Yield of Bafna Pharmaceuticals Ltd is 0.00 %.

    What is the ROCE of Bafna Pharmaceuticals Ltd?

    The ROCE of Bafna Pharmaceuticals Ltd is 15.9 %.

    What is the ROE of Bafna Pharmaceuticals Ltd?

    The ROE of Bafna Pharmaceuticals Ltd is 16.4 %.

    What is the Face Value of Bafna Pharmaceuticals Ltd?

    The Face Value of Bafna Pharmaceuticals Ltd is 10.0.

    About the Author

    Author Avatar
    Getaka

    Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

    Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Bafna Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE